Zusammenfassung
Der Morbus Parkinson ist eine fortschreitende neurodegenerative Krankheit des extrapyramidalmotorischen Systems, von der 1% der Bevölkerung über 65 Jahre betroffen ist. Ursache ist eine in ihrer Ätiologie unbekannte Degeneration dopaminerger Neurone in der Substantia nigra, die zu einem „stria talen“ Dopaminmangelsyndrom führt und mit einer erhöhten cholinergen Aktivität einhergeht. Die klassischen Symptome sind Akinese, Rigor und Tremor.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Birkmayer W, Hornykiewicz O (1961): Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien klin Wschr 78: 787–788
Canadian Agency for Drugs and Technologies in Health (2015): CADTH Final Recommendation: Rotigotine –Resubmission. Internet: https://www.cadth.ca/rotigotine-7
Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003; (1):CD003468
Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554
Deutsche Gesellschaft für Neurologie (2016): Leitlinien für Diagnostik und Therapie in der Neurologie: Idiopathisches Parkinson-Syndrom, Entwicklungsstufe: S3. Internet: https://www.dgn.org/leitlinien/3219-030-010-idiopathisches-parkinson-syndrom
European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf
Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators (2007): Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404
Hoy SM, Keating GM (2012): Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs 72: 643–669
Huntington Study Group (2006): Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366–372
Kalia LV, Lang AE (2015): Parkinson’s disease. Lancet 386: 896–912
Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;(2):CD003735
Müller-Vahl KR (2007): Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms. Eine Standortbestimmung. Nervenarzt 78: 264–271
Ossig C, Reichmann H (2013): Treatment of Parkinson’s disease in the advanced stage. J Neural Transm 120: 523–529
Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, Nyholm D, Sydow O, Wainwright M, Widner H, Johansson A (2012): Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126: e29–33
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators (2007): Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–520
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491
Rascol O, Lozano A, Stern M, Poewe W (2011): Milestones in Parkinson’s disease therapeutics. Mov Disord 26: 1072–1082
Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158
Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M (2011): Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011 Mar 16; (3): CD006009
Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50 (Suppl 6): S18-S22; discussion S44–S48
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010): Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68: 18–27
The Parkinson Study Group (2004a): Levodopa and the progression of Parkinson‹s disease. N Engl J Med 351: 2498–2508
The Parkinson Study Group (2004b): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag GmbH Germany
About this chapter
Cite this chapter
Schwabe, U. (2017). Parkinsonmittel. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_40
Download citation
DOI: https://doi.org/10.1007/978-3-662-54630-7_40
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-54629-1
Online ISBN: 978-3-662-54630-7
eBook Packages: Medicine (German Language)